ATRA and genistein synergistically inhibit the metastatic potential of human lung adenocarcinoma cells

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 3, 2015, Pages 4220-4227

  Cheng, Ji ^a   Qi, Jun ^b   Li, Xue Tao ^c   Zhou, Kun ^a   Xu, Jing Han ^d   Zhou, Yong ^a   Zhang, Guo Qiang ^a   Xu, Jian Ping ^a   Zhou, Ren Jie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Chongqing Cancer Institute   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d Chongqing Institute of Traditional Chinese Medicine   (China)

Author keywords

All trans retinoic acid; Genistein; ICAM 1; Lung carcinoma; Metastatic potential; MUC1

Indexed keywords

CYCLIN DEPENDENT KINASE 4; GENISTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MUCIN 1; PROTEIN BAX; PROTEIN BCL 2; RETINOBLASTOMA PROTEIN; RETINOIC ACID;

A549 CELL LINE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG METASTASIS; METASTASIS INHIBITION; METASTASIS POTENTIAL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING;

EID: 84929338081     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Connolly RM, Nguyen NK and Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res 2013; 19: 1651-1659.
2. Mahmoud AM, Zhu T, Parray A, Siddique HR, Yang W, Saleem M and Bosland MC. Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS One 2013; 8: e78479.
3. Pavese JM, Farmer RL and Bergan RC. Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 2010; 29: 465-482.
4. Kalemkerian GP, Jiroutek M, Ettinger DS, Dorighi JA, Johnson DH and Mabry M. A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma. Cancer 1998; 83: 1102-1108.
5. Hind CK, Carter MJ, Harris CL, Chan HT, James S, Cragg MS. Role of the pro-survival molecule bfl-1 in melanoma. Int J Biochem Cell Biol 2015; 59: 94-102.
6. Asmarinah A, Paradowska-Dogan A, Kodariah R, Tanuhardja B, Waliszewski P, Mochtar CA, Budiningsih Y, Weidner W and Hinsch E. Expression of the Bcl-2 family genes and complexes involved in the mitochondrial transport in prostate cancer cells. Int J Oncol 2014; 45: 1489-1496.
7. Eichhorn JM, Alford SE, Sakurikar N and Chambers TC. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. Exp Cell Res 2014; 322: 415-424.
8. Chatterjee A, Chattopadhyay D and Chakrabarti G. Mir-16 targets Bcl-2 in paclitaxel-resistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. Cell Signal 2014; 27: 189-203.
9. Li Z, Qu L, Zhong H, Xu K, Qiu X and Wang E. Low expression of Mig-6 is associated with poor survival outcome in NSCLC and inhibits cell apoptosis via ERK-mediated upregulation of Bcl-2. Oncol Rep 2014; 31: 1707-1714.
10. Adams JM and Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001; 26: 61-66.
11. Trenti A, Grumati P, Cusinato F, Orso G, Bonaldo P and Trevisi L. Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2. Biochem Pharmacol 2014; 89: 197-209.
12. Fokkema E, Timens W, de Vries EG, de Jong S, Fidler V, Meijer C and Groen HJ. Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung Cancer 2006; 52: 241-247.
13. Jiang H, Zhao PJ, Su D, Feng J and Ma SL. Paris saponin I induces apoptosis via increasing the Bax/Bcl-2 ratio and caspase-3 expression in gefitinib-resistant non-small cell lung cancer in vitro and in vivo. Mol Med Rep 2014; 7: 2265-2272.
14. Zhou RJ, Yang XQ, Wang D, Zhou Q, Xia L, Li MX, Zeng LL, Wang G and Yang ZZ. Anti-tumor effects of all-trans retinoic acid are enhanced by genistein. Cell Biochem Biophys 2012; 62: 177-184.
15. Zhang TF, Yu SQ, Deuel TF and Wang ZY. Constitutive expression of Rb associated protein 46 (RbAp46) reverts transformed phenotypes of breast cancer cells. Anticancer Res 2002; 23: 3735-3740.
16. Ertesvag A, Engedal N, Naderi S and Blomhoff HK. Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion. J Immunol 2002; 169: 5555-5563.
17. Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S and Hursting SD. Low-dose genistein induces cyclin-dependent kinase inhibitors and G1 cell-cycle arrest in human prostate cancer cells. Mol Carcinog 2000; 29: 92-102.
18. Imran M, Park TJ and Lim IK. IS21/BTG2/PC3 enhances downregulation of c-Myc during differentiation of HL-60 cells by activating Erk1/2 and inhibiting Akt in response to all-trans-retinoic acid. Eur J Cancer 2012; 48: 2474-2485.
19. Esposito V, Groeger AM, De Luca L, Di Marino M, Santini D, Marchei P, Baldi F, Wolner E and Baldi A. Expression of surface protein receptors in lung cancer. Anticancer Res 2001; 22: 4039-4043.
20. Hou CH, Lin FL, Tong KB, Hou SM and Liu JF. Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway. Biochem Pharmacol 2014; 89: 453-463.
21. Moase EH, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, Ding L, Krantz M and Allen TM. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta 2001; 1510: 43-55.
22. Hirasawa Y, Kohno N, Yokoyama A, Kondo K, Hiwada K and Miyake M. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161: 589-594.
23. Cascio S, Farkas AM, Hughey RP and Finn OJ. Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration. Oncotarget 2013; 4: 1686.
24. Kaira K, Nakagawa K, Ohde Y, Okumura T, Takahashi T, Murakami H, Endo M, Kondo H, Nakajima T and Yamamoto N. Depolarized MUC1 expression is Closely associated with hypoxic markers and poor outcome in resected non-small cell lung cancer. Int J Surg Pathol 2012; 20: 223-232.
25. Nagai S, Takenaka K, Sonobe M, Ogawa E, Wada H and Tanaka F. A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol 2006; 1: 46-51.